An interventional study of Endothelin-1 and BQ-123 and BQ-788 in Coronary Disease, sponsored by University of Edinburgh. Completed at 1 site in Sweden. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-17.
Sponsored by University of Edinburgh · Not applicable, Interventional, and Basic science
The purpose of this study is to identify the role of endothelin 1 (a natural vasoconstrictor) in the adverse vascular effects demonstrated after exposure to air pollution
Air pollution is a major problem, and can be linked to around 5% of all deaths worldwide each year. There are strong associations between air pollution exposure and heart disease but we do not yet understand how these harmful effects are mediated. Understanding this mechanism is likely to have a major impact on the way we treat patients with heart disease and have the potential to shape future environmental health policy. The upregulation of Endothelin-1 provides a plausible mechanism for these harmful effects, and we plan to investigate this in more depth in the human forearm following exposure to diesel exhaust.
2,867 studies on the registry are indexed under Coronary Disease; 309 are open to participants now.
This study's enrollment of 15 is below the median of 124 across 1,601 interventional studies indexed under Coronary Disease.
Browse Coronary Disease studies →University of Edinburgh is the lead sponsor of 403 studies on the registry; 65 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
Drug: Endothelin-1
1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
Drug: BQ-123 and BQ-788
1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
Drug: Endothelin-1
1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
Drug: BQ-123 and BQ-788
Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography
Also known as: ET-1, American Peptides - 88-1-10 (ET-1)
Drug pages: cyclo(Trp-Asp-Pro-Val-Leu) · BQ 788
1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography
Also known as: American Peptides - 88-2-10 (BQ-123), American Peptides - 88-2-55 (BQ-788)
Change in forearm blood flow following infusion of endothelin-1 or the endothelin receptor antagonists BQ-123 & BQ-788
Time frame: 2 hours after exposure
24 hour mean blood pressure (ambulatory monitoring)
Time frame: 24 hours following the exposure
Systemic endothelin-1 and big endothelin-1 concentrations
Time frame: At baseline, and immediately, 1, 2, 3, 4, 6 and 24 hours after exposure
Changes in arterial stiffness (pulse-wave velocity)
Time frame: During and for the 1 hour after the exposure
The record gives a start of Mar 2008, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Endothelin 1 · cyclo(Trp-Asp-Pro-Val-Leu) · BQ 788